Chryseomonas luteola bloodstream infection in a pediatric patient with pulmonary arterial hypertension receiving intravenous treprostinil therapy

Infection

Volumn 41, Issue 3, 2013, Pages 719-722

  Wen, A Y ^a   Weiss, I K ^a   Kelly, R B ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Bloodstream infection; Chryseomonas luteola; Pulmonary arterial hypertension; Treprostinil

Indexed keywords

ADENYLATE DEHYDROGENASE; AMIKACIN; ANTIINFECTIVE AGENT; BOSENTAN; CEFTRIAXONE; COTRIMOXAZOLE; DILUENT; ESCULIN; FUROSEMIDE; GENTAMICIN; MEROPENEM; OXIDOREDUCTASE; PIPERACILLIN PLUS TAZOBACTAM; STERILE WATER; TREPROSTINIL; UNCLASSIFIED DRUG; VANCOMYCIN;

ADOLESCENT; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BLOOD CULTURE; BLOODSTREAM INFECTION; CASE REPORT; CHRYSEOMONAS LUTEOLA; CONTINUOUS INFUSION; COUGHING; DIARRHEA; DISEASE ASSOCIATION; DYSPNEA; ECHOCARDIOGRAPHY; EXERCISE TOLERANCE; FATIGUE; FEVER; HEART MUSCLE CONTRACTILITY; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE PRESSURE; HUMAN; INTENSIVE CARE; MALE; MINIMUM INHIBITORY CONCENTRATION; MUSCLE CRAMP; PSEUDOMONAS; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; RASH; RISK REDUCTION; SEPSIS; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ANTI-BACTERIAL AGENTS; ANTIHYPERTENSIVE AGENTS; BACTEREMIA; BLOOD; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; MALE; PSEUDOMONAS; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME;

EID: 84878859594     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-012-0399-2     Document Type: Article

References (16)

1. Centers for Disease Control and Prevention. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States, 2003-2006. MMWR Morb Mortal Wkly Rep. 2007;56:170-2.
2. Badesch DB, McLaughlin VV, Delcroix M, Vizza CD, Olschewski H, Sitbon O, Barst RJ. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:56S-61S.
3. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Koch G, Li S, Clayton LM, Jöbsis MM, Blackburn SD Jr, Crow JW, Long WA. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-302.
4. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA. 1997;94:4312-7.
5. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D, Mandayam S, Ginzton LE, Brundage BH. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. 1997;30:343-9.
6. Rosenzweig EB, Barst RJ. Idiopathic pulmonary arterial hypertension in children. Curr Opin Pediatr. 2005;17:372-80.
7. Libby P, Warner SJ, Friedman GB. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest. 1988;81:487-98.
8. Rich JD, Glassner C, Wade M, Coslet S, Arneson C, Doran A, Gomberg-Maitland M. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest. 2012;141:36-42.
9. 2 analogues on Th1- and Th2-related chemokines in monocytes via epigenetic regulation. J Mol Med (Berl). 2011;89:29-41.
10. Zaccardelli D, Phares K, Jeffs R, Doran A, Wade M. Stability and antimicrobial effectiveness of treprostinil sodium in sterile diluent for flolan. Int J Clin Pract. 2010;64:885-91.
11. Kodama K, Kimura N, Komagata K. Two new species of Pseudomonas: P. oryzihabitans isolated from rice paddy and clinical specimens and P. luteola isolated from clinical specimens. Int J Syst Bacteriol. 1985;35:467-74.
12. Rahav G, Simhon A, Mattan Y, Moses AE, Sacks T. Infections with Chryseomonas luteola (CDC group Ve-1) and Flavimonas oryzihabitans (CDC group Ve-2). Medicine (Baltimore). 1995;74:83-8.
13. Kostman JR, Solomon F, Fekete T. Infections with Chryseomonas luteola (CDC group Ve-1) and Flavimonas oryzihabitans (CDC group Ve-2) in neurosurgical patients. Rev Infect Dis. 1991;13:233-6.
14. Gaschet A, Engrand C, Piau C, Violette J, Bétrémieux P, Tattevin P, Pladys P, Donnio PY, Jolivet-Gougeon A. Multiple brain abscesses caused by Pseudomonas luteola. Pediatr Infect Dis J. 2009;28:1144-6.
15. Chihab W, Alaoui AS, Amar M. Chryseomonas luteola identified as the source of serious infections in a Moroccan University Hospital. J Clin Microbiol. 2004;42:1837-9.
16. Rastogi S, Sperber SJ. Facial cellulitis and Pseudomonas luteola bacteremia in an otherwise healthy patient. Diagn Microbiol Infectious Dis. 1998;32:303-5.